Pieris Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview

Palvella Therapeutics

24/02/2023 17:35

* Pieris Pharmaceuticals Inc  PIRS.OQ   PIRS.O  is expected
to show a fall in quarterly revenue when it reports  results on
February 27 (estimated). 
    * The Boston Massachusetts-based  company is expected to
report  a
22.9% decrease in revenue to $6.511 million from $8.44 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Pieris
Pharmaceuticals
Inc is for a loss of 23 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $7​, above​ its last closing price
of $1.49. ​​​

This summary was machine generated February 24 at 17:35 GMT. 
All figures in US dollars  unless otherwise stated